AEterna Zentaris Inc. (USA)  

(Public, NASDAQ:AEZS)   Watch this stock  
Find more results for aezs
3.41
-0.09 (-2.57%)
May 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.39 - 3.59
52 week 2.60 - 31.38
Open 3.47
Vol / Avg. 109,289.00/200,868.00
Mkt cap 34.12M
P/E     -
Div/yield     -
EPS -22.23
Shares 9.94M
Beta 1.74
Inst. own 179%
Aug 10, 2016
Q2 2016 AEterna Zentaris Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 10, 2016
Q1 2016 AEterna Zentaris Inc Earnings Call
May 9, 2016
Q1 2016 AEterna Zentaris Inc Earnings Release
Mar 30, 2016
Q4 2015 AEterna Zentaris Inc Earnings Call
Mar 29, 2016
Q4 2015 AEterna Zentaris Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1519.01% -9216.15%
Operating margin -2888.84% -6400.73%
EBITD margin - -6338.16%
Return on average assets -30.86% -101.54%
Return on average equity -77.78% -278.28%
Employees 56 -
CDP Score - -

Address

1 Ville-Marie Pl Suite 2500
MONTREAL, QC H3B 1R1
Canada
+1-514-8474516 (Phone)
+1-418-9489191 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women's health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.

Officers and directors

David A. Dodd Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Dennis Turpin CA Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Philip Allen Theodore Senior Vice President, Chief Administrative Officer, General Counsel
Age: 61
Bio & Compensation  - Reuters
Richard Sachse M.D., Ph.D. Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Bio & Compensation  - Reuters
Jude Dinges Chief Commercial Officer, Senior Vice President
Bio & Compensation  - Reuters
Genevieve Lemaire Chief Accounting Officer, Vice President - Finance
Bio & Compensation  - Reuters
Michael Teifel Vice President - Non-Clinical Sciences
Bio & Compensation  - Reuters
Juergen H. L. Ernst Lead Independent Director
Age: 76
Bio & Compensation  - Reuters
Michael A. Cardiff Director
Bio & Compensation  - Reuters
Kenneth E. Newport CPA Director
Age: 49
Bio & Compensation  - Reuters